2620-62-4
Chemical Structure
N6,N6-Dimethyladenosine
- CAS No.: 2620-62-4
- Formula:C12H17N5O4
- Molecular Weight:295.29
IUPAC Name: (2R,3R,4S,5R)-2-(6-(dimethylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
InChIKey: WVGPGNPCZPYCLK-WOUKDFQISA-N
SMILES: O[C@H]1[C@@H](O)[C@H](N2C(N=CN=C3N(C)C)=C3N=C2)O[C@@H]1CO
Biological Activity: N6,N6-Dimethyladenosine, a modified ribonucleoside, is an endogenous A3 adenosine receptor ligand. N6,N6-Dimethyladenosine is an AKT inhibitor with antitumor effects. N6, N6-Dimethyladenosine targets SARS-CoV-2 entry protein ADAM17. N6, N6-Dimethyladenosine robustly inhibits AKT signaling in a variety of non-small cell lung cancer cell lines[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
N6,N6-Dimethyladenosine | 99.66% | N6,N6-Dimethyladenosine, a modified ribonucleoside, is an endogenous A3 adenosine receptor ligand. N6,N6-Dimethyladenosine is an AKT inhibitor with antitumor effects. N6, N6-Dimethyladenosine targets SARS-CoV-2 entry protein ADAM17. N6, N6-Dimethyladenosine robustly inhibits AKT signaling in a variety of non-small cell lung cancer cell lines. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N6,N6-Dimethyladenosine (Standard) | 99.94% | N6,N6-Dimethyladenosine (Standard) is the analytical standard of N6,N6-Dimethyladenosine (HY-101984). This product is intended for research and analytical applications. N6,N6-Dimethyladenosine, a modified ribonucleoside, is an endogenous A3 adenosine receptor ligand. N6,N6-Dimethyladenosine is an AKT inhibitor with antitumor effects. N6, N6-Dimethyladenosine targets SARS-CoV-2 entry protein ADAM17. N6, N6-Dimethyladenosine robustly inhibits AKT signaling in a variety of non-small cell lung cancer cell lines. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. He J, et al. Antiviral Potential of Small Molecules Cordycepin, Thymoquinone, and N6, N6-Dimethyladenosine Targeting SARS-CoV-2 Entry Protein ADAM17. Molecules. 2022 Dec 19;27(24):9044. [Content Brief]
- [2]. Vaden RM, et al. FUSION-Guided Hypothesis Development Leads to the Identification of N⁶,N⁶-Dimethyladenosine, a Marine-Derived AKT Pathway Inhibitor. Mar Drugs. 2017 Mar 15;15(3):75. [Content Brief]
